Neuralstem Inc (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, has named David J Mazzo, PhD as its director effective 12 June 2019, it was reported yesterday.

Dr Mazzo will replace Stanley Westreich, who is retiring on the effective date.

Dr Mazzo has more than 30 years of experience in the pharmaceutical industry, and currently serves as chief executive officer of Caladrius Biosciences. He has also served as: chief executive officer and as a member of the board of directors of Regado Biosciences Inc, a NASDAQ-listed biopharmaceutical company; president, chief executive officer and a director of Eterna Zentaris Inc and president, chief executive officer and a director of Chugai Pharma USA LLC, a biopharmaceutical company which was the US subsidiary of Chugai Pharmaceutical Co Ltd of Japan. In addition, Dr Mazzo has also held senior management and executive positions in a number of public and private pharmaceutical and biotech companies.